Last reviewed · How we verify
In Vivo CAR-T Therapy
At a glance
| Generic name | In Vivo CAR-T Therapy |
|---|---|
| Also known as | HN2301 |
| Sponsor | Tcelltech Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases (NA)
- Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies (PHASE1)
- In Vivo CAR-T for Refractory Graves' Disease (EARLY_PHASE1)
- Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG) (NA)
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG) (PHASE1)
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (PHASE1)
- PIC1 Injection Therapy for Relapsed/Refractory B-NHL (PHASE1)
- CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- In Vivo CAR-T Therapy CI brief — competitive landscape report
- In Vivo CAR-T Therapy updates RSS · CI watch RSS
- Tcelltech Inc. portfolio CI